Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramiro Garzon

Showing results (101-110 of 134) with videos related to

Pageof 14
Sort By:
The New England Journal of Medicine|May 3, 2008
MicroRNA expression in cytogenetically normal acute myeloid leukemiaGuido Marcucci, Michael D Radmacher, Kati Maharry, et al.
Blood|February 13, 2009
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1Ramiro Garzon, Shujun Liu, Muller Fabbri, et al.
JCI Insight|March 20, 2020
PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host diseaseKatiri J Snyder, Nina C Zitzer, Yandi Gao, et al.
Nature Communications|June 19, 2026
ATF4 coordinates amino acid and nucleotide synthesis with selective protein translation to ensure proper DNA replication timing in leukemia cellsJacklyn M Huhn, Liana Valin, Mary Basse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patientsGuido Marcucci, Kati S Maharry, Klaus H Metzeler, et al.
Haematologica|March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineWilliam Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Genome Research|March 12, 2021
DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemiaBrian Giacopelli, Min Wang, Ada Cleary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2010
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Kati Maharry, Michael D Radmacher, et al.
Blood|May 9, 2012
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemiaWilliam Blum, Sebastian Schwind, Somayeh S Tarighat, et al.
Pageof 14

Showing results (101-110 of 134) with videos related to

Sort By:
Pageof 14
The New England Journal of Medicine|May 3, 2008
MicroRNA expression in cytogenetically normal acute myeloid leukemiaGuido Marcucci, Michael D Radmacher, Kati Maharry, et al.
Blood|February 13, 2009
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1Ramiro Garzon, Shujun Liu, Muller Fabbri, et al.
JCI Insight|March 20, 2020
PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host diseaseKatiri J Snyder, Nina C Zitzer, Yandi Gao, et al.
Nature Communications|June 19, 2026
ATF4 coordinates amino acid and nucleotide synthesis with selective protein translation to ensure proper DNA replication timing in leukemia cellsJacklyn M Huhn, Liana Valin, Mary Basse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patientsGuido Marcucci, Kati S Maharry, Klaus H Metzeler, et al.
Haematologica|March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineWilliam Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Genome Research|March 12, 2021
DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemiaBrian Giacopelli, Min Wang, Ada Cleary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2010
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Kati Maharry, Michael D Radmacher, et al.
Blood|May 9, 2012
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemiaWilliam Blum, Sebastian Schwind, Somayeh S Tarighat, et al.
Pageof 14